Worldwide Vascular Endothelial Growth Factor Inhibitor Industry to 2030 – Players Include Regeneron Pharmaceuticals, Astrazeneca & Novartis Among Others – ResearchAndMarkets.com | Financial Buzz

Worldwide Vascular Endothelial Growth Factor Inhibitor Industry to 2030 – Players Include Regeneron Pharmaceuticals, Astrazeneca & Novartis Among Others – ResearchAndMarkets.com

The “Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market.

The global vascular endothelial growth factor (VEGF) inhibitor market reached a value of nearly $30,312.6 million in 2020, having increased at a compound annual growth rate (CAGR) of 7.8% since 2015. The market is expected to grow from $30,312.6 million in 2020 to $46,635.5 million in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $63,375.9 million in 2030.

Companies Mentioned

  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • Astrazeneca Plc.
  • Novartis AG

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

This report describes and explains the global vascular endothelial growth factor (VEGF) inhibitor market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025. The top opportunities in segment by route of administration will arise in the oral segment, which will gain $8,830.4 million of global annual sales by 2025. The top opportunities in segment by application will arise in the oncology segment, which will gain $12,263.3 million of global annual sales by 2025. The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

Market-trend-based strategies for the vascular endothelial growth factor (VEGF) inhibitor market include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in R&D activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (AMD) in order to improve patient welfare.

Key Topics Covered:

1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

6.1.1. Segmentation by Geography

6.1.2. Segmentation by Drug Type

6.1.3. Segmentation by Route of Administration

6.1.4. Segmentation by Application

7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics

7.1. Segmentation by Drug Type

7.2. Segmentation by Route of Administration

7.3. Segmentation by Application

8. COVID Impact on the Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

8.1. Negative Impact on VEGF Market Due to Deferred Care

8.2. Impact on Major VEGF Companies in the Market

9. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends and Strategies

9.1. Use of Combination Therapy

9.2. Furthering Innovation Through Collaboration

9.3. Robust Research & Development

9.4. Increasing Biosimilar Approvals

9.5. Less Frequent Dosing for Wet Age-Related Macular Degeneration (AMD)

10. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size and Growth

10.1. Market Size

10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

10.3. Forecast Market Growth, 2020 – 2025, 2030F Value ($ Million)

11. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation

11.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type,

11.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Route of Administration

11.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Application

12. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Regional and Country Analysis

12.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, by Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

12.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, by Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

For more information about this report visit https://www.researchandmarkets.com/r/hxns9t

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900